Genomic Vision Provides Strategy Update - Seite 2

This AI strategy, backed by strategic partnerships, places the Company at the vanguard of the genomic industry, a global market expected to reach $62.9 billion by 2028. Genomic Vision’s forward-looking approach underscores its commitment to lead the AI-driven genomics revolution, ensuring the Company remains a frontrunner in this rapidly growing industry. The addressable market for Genomic Vision technology and services is estimated at $4.8 billion and growing at two-digit figures compound annual growth rate.

To expand the potential applications of its DNA analysis technology further, Genomic Vision initiated a four-year scientific program in collaboration with the Cancer Research Center of Marseille. This program, initiated in 2022, focuses on the development of companion diagnostic tests using Genomic Vision’s TeloSizer technology, a novel method for the high-precision measurement of telomere length and distribution. This technology has the potential to reveal connections between telomere length and the onset and severity of diseases such as cancer and age-associated diseases. The collaboration is ongoing with updates expected towards the end of the four-year program in 2026.

Alongside next-generation technology developments, Genomic Vision is increasing engagement with industry and academic institutions, fostering the development of its platform and amplifying its reach within the biomanufacturing ecosystem. To this end, Genomic Vision was pleased to announce that its innovative technology was confirmed as highly accurate for the quantitative analysis of genomic events of up to 10 kilobases by the US National Institute of Standards and Technology (NIST) in February 2023. In addition to this, the Company became a member of France Biolead Association in April 2023, providing access to a network of industry leaders and potential partnering opportunities within the bioproduction sector.

Aaron Bensimon, Chief Executive Officer of Genomic Vision, said: “Genomic Vision is committed to delivering high-quality genomic solutions that enhance the quality control and bioproduction standards of advanced gene therapies. Through precise single-molecule DNA visualization and quantification, our molecular combing technology facilitates the analysis of structural and functional genome modifications, delivering accurate results for engineered cell lines. Working together with our partners and customers, we aim to unlock the full potential of advanced therapies, with the ultimate goal of empowering breakthroughs in genomic research and improving patients’ lives.”